Name: ABT 702 dihydrochloride
Price: 438.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50: 1.7 nM for adenosine kinase
    Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. ABT 702 is a novel, potent nonnucleoside AK inhibitor.
    In vitro: ABT 702 was active both in inhibiting AK (IC50 ) 1.7 nM) and ADO phosphorylation in the intact cells (IC50 ) 50 nM). ABT 702 was also highly selective for AK inhibition as compared to other sites of ADO action including ADA, ADO receptors, and ADO transport sites [1].
    In vivo: ABT 702 had dose-dependent antinociceptive and antiinflammatory actions in a variety of animal models of nociceptive, inflammatory, and neuropathic pain. ABT 702 is the first of a novel class of potent, selective, non-nucleoside, orally active AK inhibitors that have potent antinociceptive effects in animal models [1].
    Clinical trial: Up to now, ABT 702 is still in the preclinical development stage.
- Properties
  - Alternative Name
    
    5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine dihydrochloride
    
    CAS Number
    
    1188890-28-9
    
    Molecular Formula
    
    C22H19N6OBr·2HCl
    
    Molecular Weight
    
    536.26
    
    Appearance
    
    Orange solid
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥107.2 mg/mL in DMSO; ≥9.84 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

ABT 702 dihydrochloride

ABT 702 dihydrochloride

Background

We Also Recommend

Astressin 2B

FK 888